
The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
Morphine Sulfate (Kadian)
Celecoxib (Celebrex)
Fentanyl Transdermal (Duragesic)
Pregabalin (Lyrica)





